sur EURAZEO (EPA:RF)
EURAZEO and Kurma Partners Invest in PanTera's EUR 93 Million Financing for Actinium-225 Production
Paris, September 11, 2024 – The Nov Santé Actions Non Cotées Fund, managed by Eurazeo, has finalized its second Growth Equity investment in PanTera. This EUR 93 million fundraising includes contributions from Eurazeo and Kurma Partners, giving them a minority stake in the company alongside EQT, the lead arranger.
Founded from a 2019 partnership between IBA and SCK-CEN, PanTera aims to produce Actinium-225, a promising cancer-fighting radioisotope. Currently, global production of Actinium-225 is about 3Ci per year, but PanTera plans to produce 1.5-2Ci annually from 2025. By 2029, they aim to provide enough for 100,000 patients annually.
The investment underscores Eurazeo's commitment to healthcare innovation. Arnaud Vincent, Managing Director at Eurazeo, highlighted the potential of Actinium-225 to revolutionize cancer treatment, and PanTera's role in advancing European healthcare sovereignty.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de EURAZEO